Are peptides legal in the military?

What DoD Instruction 6130.06 says about prohibited ingredients

DoD Instruction 6130.06, Use of Dietary Supplements in the DoD, took effect March 9, 2022. It sets one Defense Department list of prohibited dietary supplement ingredients. Operation Supplement Safety (OPSS), a DoD program at the Uniformed Services University, hosts that list online.

The instruction says service members will not use products on the list unless a DoD health care provider authorizes it. A separate exception covers approved DoD research studies. The instruction says exception requests go through the first officer at grade O-5 or higher in the chain of command. A decision comes within 120 days.

The instruction says service members can be prosecuted for using dietary supplements that contain listed substances. It cites Chapter 47 of Title 10, U.S. Code. That chapter is the Uniform Code of Military Justice, the military's criminal law.

It tells the Secretary of each military department to issue a punitive regulation, a rule that can be enforced with military punishment. Commissaries, exchanges and other DoD stores may not sell products with listed ingredients. DoD health care providers must record a service member's supplement use in the electronic health record.

The use rule names service members. It does not name family members.

What the DoD prohibited list includes

OPSS says the list holds more than 800 substances. It includes controlled substances and many drugs found in supplements. The instruction says it also includes selected prescription or unapproved drugs from the World Anti-Doping Agency (WADA) Prohibited List, sections S0 through S5.

The list page says it was last updated on 3 September 2026. The instruction says the list will be updated quarterly and when new scientific evidence or an FDA action occurs. OPSS says entries show other names that may appear on a label.

The list page adds a broader rule. It says controlled substances and drugs, including prescription, over-the-counter and unapproved drugs, are all prohibited for use in dietary supplements. OPSS asks service members to use its Ask the Expert service when a status is unclear.

Which peptides the DoD list names

The list search on the OPSS site was checked one name at a time on November 2, 2026. Each row below shows the list's name for the substance, its reason and other names it shows. Reasons are copied word for word. Long name lists are shortened.

Most peptide rows give the reason "WADA S2: Peptide Hormones, Growth Factors, etc." That is the WADA section for peptide hormones and related substances. BPC-157 is listed under WADA S0, the section for non-approved substances. MOTS-c is listed under S4, the section for hormone and metabolic modulators.

Some rows give a second reason. The HGH, tesamorelin and IGF rows also say "Prescription drug." The sermorelin row says "Discontinued drug." AOD-9604 and three IGF-1 forms add "Use or misuse prohibited under DoDI 1010.16," another DoD instruction not reviewed here.

Spelling changes the result. A search for "thymosin beta-4" with a hyphen found no row, while "thymosin" found the thymosin beta 4 row. OPSS tells readers to spell the ingredient exactly as it appears on the label.

The list is the official DoD record for these rows. Each row shows list status on November 2, 2026. The list can change after that date.

Names the list search did not return

The same November 2 search found no row for semaglutide, tirzepatide, retatrutide, melanotan, GHK-Cu, KPV or selank. A search for insulin returned only the IGF row, through its other name "insulin-like growth factor 1." A missing row does not clear a product.

An OPSS article updated March 7, 2022, names insulin, hCG, growth hormone and IGF-1 as peptide hormones. It says they are prescription medicines that do not belong in dietary supplements. It also says peptide hormones are on the DoD list and can cause serious health risks.

OPSS's GLP-1 article, posted June 3, 2026, says retatrutide and cagrilintide are investigational drugs, meaning drugs still being tested in clinical trials. It says neither has FDA approval for any use. It says they are legally available only to clinical trial patients.

The same article tells service members to avoid compounded and investigational GLP-1 drugs. Compounded drugs are mixed by a pharmacy and are not FDA-approved products. The article says compounded versions lack FDA review for safety, quality and effectiveness.

How prescription peptide medicines fit the rule

OPSS calls GLP-1 drugs, such as semaglutide and tirzepatide, prescription peptide medicines. It says they are not dietary supplements. Its ingredient index says semaglutide use might be allowed if a service member meets the prior authorization criteria. Prior authorization means approval from the military health plan before a drug is covered.

The GLP-1 article says eligibility depends on a service member's diagnosis, prior authorization or medical necessity. It says use during training, deployments or on operational platforms might not be authorized. Some cases may be allowed case by case under each service's policies.

OPSS asks service members to use providers at their installation's military treatment facility when possible. It also asks them to make sure every medicine appears in their military health record. The article says GLP-1 medicines have potentially serious side effects and that service and duty policies remain under review.

Some listed peptides are also prescription drugs, such as tesamorelin (Egrifta) and bremelanotide. The instruction's general exception is authorization by a DoD health care provider. The sources reviewed here do not describe how a provider gives that authorization for each listed drug.

What research-use labels and injected peptides mean for service members

OPSS's BPC-157 article, posted April 29, 2025, says BPC-157 products may be labeled "research chemicals" or "not for human consumption." It says service members should avoid them, and any product with a prohibited ingredient, whether taken by mouth, injection or nasal spray.

The same article says the safety and effectiveness of BPC-157 have not been thoroughly evaluated in humans. The OPSS peptide hormone article says the purity and strength of peptides sold online for "research purposes only" cannot be ensured.

The instruction defines dietary supplements as products taken by mouth. OPSS still tells service members to avoid listed ingredients however they are taken. The sources reviewed here do not say which rule covers an injected or nasal product.

An HHS policy released October 28, 2026, addresses pharmacy compounding of six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Under the federal pharmacy compounding law (section 503A), a compounded drug needs a prescription for a specific patient. The policy text reviewed here does not mention the Defense Department.

On November 2, the DoD list still had rows for five of those six. The sources reviewed here do not say whether a civilian prescription counts as DoD health care provider authorization. A military health care provider or OPSS can answer that for one person.

Where this answer stops

The list names ingredients. OPSS says to search one ingredient at a time, spelled as on the label, and not to search a brand name. The instruction tells each military department to issue a punitive regulation. Those regulations were not reviewed here.

The sources reviewed here do not explain how the use rule applies to each reserve, National Guard or civilian status. They also do not say which rule covers injected products sold outside a pharmacy.

The list changes over time. OPSS's Ask the Expert service and a military health care provider can answer a question about one person's situation. If a list row or record cited here has changed, report it through the corrections page.